Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma

Kim, Hyeonjong; Lee, Kang Han; Shim, Hyun Jeong; Hwang, Eu Chang; Choi, Yoo‐Duk; Bang, Hyun-Jin; Cho, Sang‐Hee; Chung, Ik‐Joo; Hwang, Jun Eul; Lee, Myung Ah; Bae, Woo Kyun

doi:10.4068/cmj.2022.58.1.29

Cited by 6 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Counts of lymphocytes, neutrophils, platelets, and monocytes are all included in a complete blood count. Over the past decade, there has been substantial evidence that CBC-based biomarkers, such as NLR and PLR, have good prognostic value for a variety of cancers ( 44 – 47 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Qi,

Qiao,

Song

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe newly discovered pan-immune-inflammation value (PIV) has been illustrated to have good prognostic value for cancer patient prognosis. However, the prognostic usefulness of PIV in breast cancer patients is unknown. As a result, to aid the clinic in providing a distinctive and trustworthy biomarker to better assess breast cancer patient’s prognosis, we conducted this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients.MethodsWe conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to April 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis.ResultsA total of eight articles, involving 2953 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 2.045, 95% CI: 1.355-3.086, P = 0.001) and PFS (HR: 1.466, 95% CI: 1.163-1.848, P = 0.001). Besides, the PIV value was negatively correlated with the efficacy of neoadjuvant chemotherapy. Sensitivity analysis showed that the results of this study were reliable and stable.ConclusionsPIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Qi,

Qiao,

Song

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…NLR is one of the most accepted prognostic indices and has a positive correlation to disease severity, progress, and mortality, reflecting the immune system's sufficiency and its ability to "fight" inflammation. It is thus applicable to a variety of disease conditions, from carcinomas to inflammatory bowel and cardiovascular diseases [48][49][50][51][52][53]. In a recent study of ours on cardiac surgery patients, the NLR values on post-operative days 5 and 7 demonstrated significant discriminatory efficacy for predicting mortality within 90 days [54].…”

Section: Discussionmentioning

confidence: 86%

The Effect of Probiotics on the Prognostication of the Neutrophil-to-Lymphocyte Ratio in Severe Multi-Trauma Patients

Menni,

Tzikos,

Fyntanidou

et al. 2024

JPM

View full text Add to dashboard Cite

Background: The ratio of neutrophils to lymphocytes [NLR] is one of the most accepted prognostic indices and demonstrates a positive correlation with the severity of a disease. Given that probiotics exerted immunomodulatory properties and thus positively affected lymphocytopenia induction in severely ill patients, we performed a post hoc analysis in the ProVAP protocol to investigate whether probiotics affected the prognostication of NLR in respect to ventilator-associated pneumonia in multi-trauma patients. This cohort mandatorily involved severe traumatic brain injury patients. Methods: The white blood cell data of all patients, after being retrieved for the days 0 and 7, were statistically assessed in respect to neutrophils, lymphocytes and NLR among the 4 sub-groups of the study: placebo/no-VAP, placebo/VAP, probiotics/no-VAP, and probiotics/VAP. Results: Lymphopenia was dominant in placebo sub-groups, while an increased level of lymphocytes was prominent in probiotics sub-groups. This resulted in an increase [p = 0.018] in the NLR value in the probiotics/VAP group in relation to the probiotics/no-VAP cohort; this was an increase of half the value of the placebo/VAP [p < 0.001], while the NLR value in placebo/no-VAP group increased almost four-fold in relation to probiotics/no-VAP [p < 0.001]. Additionally, the ROC curve for probiotic-treated patients revealed a NLR7 cut-off value of 7.20 as a prognostic factor of VAP (AUC: 78.6%, p = 0.015, 95% CI: 62.6–94.5%), having a high specificity of 90.2% and a sensitivity of 42.9%. Conclusions: NLR may considered a credible prognostic biomarker in multi-trauma patients since it can evaluate the immunomodulatory benefits of probiotic treatment. However, the results of the present post hoc analysis should be interpreted meticulously until further evaluation, since they may be basically species- or strain-specific.

show abstract

“…Previous studies have shown that PLR is a valuable inflammation biomarker in various diseases (27)(28)(29)(30), and some trials have also assessed the relationship between PLR and ICH outcomes. Still, these trials reported inconsistent results, and the relationship between PLR and ICH mortality has not yet been elucidated.…”

Section: Discussionmentioning

confidence: 99%

Association between platelet-lymphocyte ratio and 90-day mortality in patients with intracerebral hemorrhage: data from the MIMIC-III database

Yuan,

Xiao,

Zhou

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundRecent evidence suggested that platelet-lymphocyte ratio (PLR) may play a role in the pathophysiology of intracerebral hemorrhage (ICH), but the results are controversial. This study aimed to explore the relationship between PLR and mortality in patients with ICH.MethodsAll data were extracted from the Medical Information Mart for Intensive Care (MIMIC) III database. The study outcome was 90-day mortality. Multivariable Cox regression analyses were used to calculate the adjusted hazard ratio (HR) with a 95% confidence interval (CI), and curve-fitting (restricted cubic spline) was used to assess the non-linear relationship.ResultsOf 1,442 patients, 1,043 patients with ICH were included. The overall 90-day mortality was 29.8% (311/1,043). When PLR was assessed in quartiles, the risk of 90-day mortality for ICH was lowest for quartile 2 (120.9 to <189.8: adjusted HR, 0.67; 95% CI: 0.48–0.93; P = 0.016), compared with those in quartile 1 (<120.9). Consistently in the threshold analysis, for every 1 unit increase in PLR, there was a 0.6% decrease in the risk of 90-day mortality for ICH (adjusted HR, 0.994; 95% CI: 0.988–0.999) in those with PLR <145.54, and a 0.2% increase in 90-day mortality (adjusted HR, 1.002; 95% CI: 1.000–1.003) in participants with PLR ≥145.54.ConclusionThere was a non-linear relationship between PLR and 90-day mortality for patients with ICH, with an inflection point at 145.54 and a minimal risk at 120.9 to <189.8 of PLR.

show abstract

Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma

Cited by 6 publications

References 34 publications

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Clinical utility of the pan-immune-inflammation value in breast cancer patients

The Effect of Probiotics on the Prognostication of the Neutrophil-to-Lymphocyte Ratio in Severe Multi-Trauma Patients

Association between platelet-lymphocyte ratio and 90-day mortality in patients with intracerebral hemorrhage: data from the MIMIC-III database

Contact Info

Product

Resources

About